Can-Fite BioPharma To Receive ~$4M From Exercise Of 1,591,738 Warrants At Reduced $2.50/ADS Price
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and
Can-Fite is getting about $4 million in cash because people are turning in special tickets (called warrants) they own at a lower price than before. This shows people still believe in the company enough to put their money in, which can help it keep going.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.